Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, July 2000, p. 645-651, Vol. 7, No. 4
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Antigenic Properties and Diagnostic Potential of
Baculovirus-Expressed Infectious Bursal Disease Virus Proteins VPX
and VP3
Jorge L.
Martínez-Torrecuadrada,1
Beatriz
Lázaro,1
José F.
Rodriguez,2 and
J. Ignacio
Casal*
INGENASA, 28037 Madrid,1 and Centro Nacional de
Biotecnologia (CSIC-UAM), 28049 Madrid,2 Spain
Received 31 January 2000/Returned for modification 4 April
2000/Accepted 5 May 2000
 |
ABSTRACT |
The routine technique for detecting antibodies specific to
infectious bursal disease virus (IBDV) is a serological evaluation by
enzyme-linked immunosorbent assay (ELISA) with preparations of whole
virions as the antigens. To avoid using complete virus in the standard
technique, we have developed two new antigens through the expression of
the VPX and VP3 genes in insect cells. VPX and especially VP3 were
expressed at high levels in insect cells and simple to purify. The
immunogenicity of both proteins was similar to that of the native
virus. VPX was able to elicit neutralizing antibodies but VP3 was not.
Purified VPX and VP3 were tested in an indirect ELISA with more than
300 chicken sera. There was an excellent correlation between the
results of the ELISA using VPX and those of the two commercial kits.
VP3 did not perform as well as VPX, and the linear correlation was
significantly lower. A comparison with the standard reference
technique, seroneutralization, showed that the indirect ELISA was more
sensitive. Therefore, VPX-based ELISA is a good alternative to
conventional ELISAs that use whole virions.
 |
INTRODUCTION |
Infectious bursal disease (IBD),
also called Gumboro disease, is a highly contagious viral
disease. It causes heavy economic losses to the poultry industry
worldwide, either by causing a high-mortality acute condition or
by leading to immunosuppression in young chickens (between 3 and 6 weeks of age) provoked by the destruction of immature B lymphocytes
within the bursa of Fabricius (14). IBD virus (IBDV) is the
etiological agent of IBD. It belongs to the genus
Avibirnavirus of the family Birnaviridae
(20). To date, two antigenically distinct serotypes (I and
II) of IBDV have been identified (12). Serotype I infects
chickens and comprises at least six different subtypes of IBDV, which
vary considerably in virulence (10). Viruses in one of these
subtypes are routinely known as variant strains, whereas viruses in the
other subtypes are known as classic strains. Serotype II infects mainly
turkeys and is not pathogenic for chickens (12).
The IBDV genome consists of two segments of double-stranded RNA
designated A and B (3). Segment A encodes a 108-kDa
polyprotein that is self-cleaved to produce VPX (48 kDa), VP3 (32 kDa),
and VP4 (28 kDa). In the mature virions, VPX is processed into VP2 (41 kDa). VP2 and VP3 are the major structural proteins of the IBDV virion.
VP2 has been identified as the main host-protective antigen of IBDV and
carries major neutralizing epitopes (1, 2, 4, 23). VP3 is
considered a group-specific antigen (2), and monoclonal
antibodies directed to VP3 were able to prevent virus attachment
(24) and to neutralize the virus (26). However,
recombinant VP3 failed to protect chickens from challenge by virulent
IBDV (21). Also, VP3 has been suggested to be the major
immunogenic protein of IBDV, since the earliest antibodies that appear
after infection with live or inactivated viruses are directed to VP3
(5).
IBDV infection in young chickens is controlled by the transfer via yolk
sac of maternal antibodies induced by the administration of live
attenuated or inactivated virus to breeder hens. To monitor the
serostatus of flocks, the enzyme-linked immunosorbent assay (ELISA) is
routinely used by diagnostic laboratories and poultry producers
worldwide (16a, 25a). Commercial ELISA kits are available to
detect antibodies for IBDV in field samples. These kits are based on
the use of whole virus preparations, which are produced by conventional
technology, as the antigen source. ELISAs based on the use of
recombinant virus antigens have been found previously to determine the
antigenic relatedness among IBDV strains (11) and to
correlate VP2 ELISA titers with protection (13). However, there are no reports of studies using recombinant expression products as ELISA antigens and field samples. Since most of the neutralizing epitopes are located on VP2, it was possible to establish a correlation among the VP2-specific antibody titers, virus neutralization titers, and protection (13).
In this study, we have prepared recombinant IBDV VPX and VP3 proteins
expressed in the baculovirus system. The value of the recombinant
proteins for diagnostic purposes was tested by indirect ELISA using
field chicken sera. The results were compared with those of commercial
kits that use whole virus preparations as test antigens and with the
seroneutralization assay, which constitutes the reference technique for
detecting IBDV antibodies.
 |
MATERIALS AND METHODS |
Cells and viruses.
Spodoptera frugiperda clone 9 (Sf9)
cells were grown and maintained in suspension or monolayer cultures at
28°C using TNM-FH media supplemented with 5% fetal calf serum (FCS)
(Gibco BRL). Wild-type and recombinant strains of Autographa
californica nuclear polyhedrosis virus were propagated in Sf9
cells according to standard methods (21).
Baby grivet monkey kidney (BGM70) cells, kindly provided by Y. M. Saif (Ohio State University), were maintained in Dulbecco's modified
Eagle's medium (DMEM) (Gibco BRL) supplemented with 10% FCS at 37°C
in a humidified 8% CO2 incubator. The serotype I IBDV SAL
strain and the serotype II IBDV OH strain, both supplied by Y. M. Saif, were grown in BGM70 cell monolayers. The Soroa strain (serotype
I) of IBDV (7, 8) was used as the starting material for the
cloning of VPX and VP3 antigens.
Sera.
Monospecific rabbit antisera against VPX/VP2 and VP3
were prepared as previously described (8). Rabbit polyclonal
antisera against baculovirus-expressed proteins were also produced.
Recombinant proteins, expressed and purified as described below, were
used to immunize rabbits by following methods described elsewhere
(18).
Blood samples from 10-week-old chickens vaccinated at 3 weeks of age
were collected from several farms in Spain and supplied
by J. C. Abad (Cobb, Madrid, Spain). IBDV-free chicken sera were
kindly provided
by O. Vainio (Turku University, Turku,
Finland).
Construction of recombinant baculoviruses.
The coding
sequences of VPX and VP3 were obtained by PCR with Vent DNA polymerase
(Biolabs), using the recombinant plasmid pFastBac/POLY as the template
(Martínez-Torrecuadrada et al., submitted for
publication). The PCR comprised 25 cycles of denaturation at
94°C for 1 min, primer annealing at 50°C for 1 min, and extension at 72°C for 2 min. The oligonucleotides used were IBDV1 (5'
TTCGATGATCACGATGACAAACCTGTCAGATC 3') and IBDV2
(5' ACTACTGATCACCCCTTGTCGGCGGCGAGAG 3'), which
cover nucleotides 1 to 1548 of open reading frame A1, for VPX gene
amplification and IBDV3 (5'
GTACCTGATCACCATGGCTGCATCAGAGTTC 3') and IBDV4 (5' GCGGCTGATCACTCAAGGTCCTCATCAGAG 3'), from nucleotides
2260 to 3039 of open reading frame A1, for VP3 gene synthesis,
according to previous reports (25). BclI sites,
shown in italics, were included to generate BamHI-compatible
ends. The resulting PCR products were subjected to digestion with
BclI and ligated into BamHI-digested baculovirus
transfer vector pAcYM1 (19). The derivative plasmids, pAcYM1-VPX.IBDV and pAcYM1-VP3.IBDV, were proof sequenced. The corresponding recombinant baculoviruses, AcVPX.IBDV and AcVP3.IBDV, were obtained according to standard procedures (15).
Protein expression analysis.
Sf9 cells were infected with
the corresponding recombinant baculovirus at a multiplicity of
infection (MOI) of 1 PFU/cell. Cells were harvested at 72 h
postinfection, washed with phosphate-buffered saline (PBS), and
resuspended in 1× loading buffer (10 mM Tris-HCl [pH 6.8], 10%
sodium dodecyl sulfate [SDS], 10%
-mercaptoethanol, 0.02%
bromophenol blue, 25% glycerol). The mixture was heated at 100°C for
5 min, and proteins were resolved by SDS-11% polyacrylamide gel
electrophoresis (PAGE) (16). Gels were stained with
Coomassie brilliant blue.
For immunoblotting analyses, proteins resolved by SDS-PAGE were
electroblotted onto a Hybond-C nitrocellulose membrane (Amersham
Pharmacia Biotech). The membrane was incubated for 1 h in blocking
solution (3% milk powder and 0.05% Tween 20 in PBS [PBST]) at
room
temperature. After blocking, filters were incubated with
rabbit
VPX/VP2- and VP3-monospecific antisera or rabbit polyclonal
sera
against recombinant VPX or VP3 for 2 h at room temperature
and
were diluted 1/500 in blocking buffer. After several washes
with PBST,
bound antibodies were detected by using alkaline phosphatase-conjugated
protein A (Sigma), nitroblue tetrazolium chloride (Gibco BRL),
and
bromochloroindolyl phosphate (Pierce) as
substrates.
Purification of IBDV VPX and VP3.
For VPX, Sf9 cells were
infected with the recombinant baculovirus AcVPX.IBDV at an MOI of 1 PFU
per cell. Cells were harvested at 72 h postinfection, washed with
PBS, and lysed by osmotic shock with 25 mM bicarbonate solution at
4°C. After removal of nuclei and cellular debris by low-speed
centrifugation, the supernatant was recovered and layered on top of a
25% (wt/vol) sucrose cushion in PES buffer {25 mM
piperazine-N,N'-bis(2-ethanesulfonic acid) [PIPES] [pH
6.2], 150 mM NaCl, and 20 mM CaCl2}; and spun at
125,000 × g for 3 h at 4°C. The pelleted
material containing the expressed recombinant protein was resuspended
in PES buffer.
For VP3, Sf9 cells were infected with AcVP3.IBDV at an MOI of 1 PFU per
cell. At 72 h postinfection, cells were centrifuged
for 10 min at
200 ×
g, washed with PBS, and lysed in 25 mM
bicarbonate
solution by osmotic shock. Cell lysates were then spun at
10,000
rpm for 15 min in an SS34 rotor, and the resulting pellet,
containing
most of the VP3 protein, was resuspended in a solution of 50 mM
Tris-HCl (pH 8.0), 0.5% glycerol, and 1 M NaCl. After
centrifugation
at 15,000 ×
g for 15 min, the
supernatant with the fraction soluble
in a high salt concentration,
highly enriched in recombinant VP3,
was collected and used as the
antigen
source.
The VPX and VP3 concentrations were estimated by Bradford assay
(Bio-Rad) and by densitometry of Coomassie blue-stained gels.
The
purity was determined by SDS-PAGE
analysis.
ELISAs.
Polystyrene microtiter plates (Labsystems, Helsinki,
Finland) were coated with purified VPX or VP3 in 50 mM carbonate buffer (pH 9.6) overnight at 4°C. The optimal coating concentration for both
antigens was 1 µg/ml, as determined by serial titration. After
absorption, the plates were washed three times with PBST. All serum
samples were diluted 1:100 and 1:500 in blocking buffer (350 mM NaCl
and PBST) and incubated for 1 h at 37°C. After four washes with
PBST, plates were treated with peroxidase-labeled anti-chicken
immunoglobulin G (Sigma) diluted 1/2,000 in blocking buffer for 1 h at room temperature. The reaction was developed by using ABTS
[2,2'-azinobis(3-ethylbenzthiazoline sulfonic acid)] (Sigma) as the
chromogen. The color development was stopped with 2% SDS after 10 min,
and the absorbance was measured at 405 nm using an ELISA reader
(Bio-Tek Instruments).
For comparison, two commercial diagnostic kits, the FlockCheck IBD
antibody test kit (IDEXX Laboratories, Westbrook, Maine)
and the
ProFlok IBD antibody test (Kirkegaard & Perry Laboratories
[KPL],
Gaithersburg, Md.) were used according to the manufacturers'
protocols.
IBDV neutralization assay.
The IBDV neutralization
capability of chicken and rabbit sera was measured by monolayer
protection assay (10). The serum samples were diluted
twofold, starting at a 1:25 dilution, in DMEM and mixed with 1.5 × 104 PFU of serotype I (SAL strain) or serotype II (OH
strain) per well (final serum dilution, 1:50). After 3 h at
37°C, the antibody-virus mixture was added to 1.5 × 104 BGM70 cells in DMEM-10% FCS per well of a 96-well
culture plate (Becton-Dickinson, Lincoln Park, N.J.). After 4 days at
37°C, cell monolayers were washed with PBS and stained for 20 min
with 1.5% crystal violet in 50% ethanol. The level of protection was evaluated by visual screening of the infected monolayers. End point
titration was determined as the reciprocal value of the highest serum
dilution that causes a 50% reduction of the cell monolayer. All
incubations were undertaken in the absence of serum complement.
Statistical analysis.
Statistical analysis was performed
with the MedCalc software package (26). Regression analysis
was used to determine the relationship between ELISA data.
 |
RESULTS |
Expression and purification of IBDV VPX.
To synthesize
recombinant VPX, Sf9 cells were infected with the baculovirus
AcVPX.IBDV and harvested 72 h later. The protein extracts were
analyzed by SDS-11% PAGE. Results are shown in Fig. 1. An extra band of approximately 48 kDa
was found by Coomassie staining to be already in the cell extract (Fig.
1A). This polypeptide was specifically recognized by the
VPX/VP2-monospecific serum (Fig. 1B), together with
high-molecular-weight aggregates and additional smaller proteins that
may represent cleavage products. To determine the correct migration
rate of the viral proteins, an IBDV-infected cell extract was also
included in the immunoblotting analysis as a control. The expressed VPX
protein comigrated with the authentic viral VPX protein (Fig. 1B).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 1.
Expression and purification of IBDV VPX and VP3 in the
baculovirus system. Crude extracts (CE) from cells infected with the
corresponding recombinant baculovirus expressing VPX or VP3 and
purified recombinant proteins (P) were electrophoresed in an SDS-11%
polyacrylamide gel and stained with Coomassie blue (A) or transferred
to nitrocellulose for immunoblotting (B). Proteins were incubated with
a mixture of monospecific rabbit antisera against VPX/VP2 and VP3 and
made to react with alkaline phosphatase-conjugated protein A. BGM70
cells infected with the SAL strain of IBDV (V) were included as a
positive control. The numbers on the left indicate the molecular mass,
in kilodaltons.
|
|
Since the expression of VPX leads to the formation of tubule-like
structures (J. L. Martínez-Torrecuadrada, unpublished
data),
we took advantage of the particulate nature of our product and
designed a sucrose cushion-based procedure to purify VPX. With
this
method, one ultracentrifugation step was enough to obtain
a VPX
preparation with a purity of about 80% (Fig.
1A). A slightly
smaller
band was also observed in the purified sample, which was
not present in
the crude extract. This protein was likely formed
as a consequence of a
further proteolytic processing of VPX, as
demonstrated by its
immunoreactivity with the VP2-specific antisera
(Fig.
1B).
Expression and purification of IBDV VP3.
To express VP3,
AcVP3.IBDV was used to infect Sf9 cells as described above. As shown in
Fig. 1, a very strong protein band was noticed in the cell extracts
with the same size as that of viral VP3 (30 kDa). The level of
expression was about 40 µg/106 cells as estimated by
visual comparison. The authenticity of the expressed product was
confirmed by immunoblotting analysis using VP3-monospecific serum. A
smaller, 24-kDa form of the VP3 protein was also detected. The origin
of this protein is not known; it may have arisen by degradation or by
in-frame internal initiation at a downstream methionine codon in the
VP3-coding sequence.
After cellular lysis by osmotic shock, it was noticeable that the major
part of the expressed protein remained insoluble in
the nuclear
fraction of the infected cells and only traces of
VP3 were detected in
the soluble cytoplasmic fraction. To increase
the solubility of VP3,
cells containing VP3 were treated with
various denaturing agents, such
as 6 M guanidine chloride or 8
M urea. However, the complete
solubilization of VP3 was achieved
only when the nuclear fraction was
resuspended in a high-ionic-strength
buffer. Using this procedure, the
purity of VP3 preparations was
found to be approximately 90% (Fig.
1A)
and the final yield of
VP3 was estimated to be 80% of the total
expressed
protein.
Immunogenicity of recombinant proteins.
To analyze whether the
immunogenicity of recombinant VPX and VP3 mimics that of the authentic
viral proteins, rabbits were immunized with purified recombinant VPX or
VP3. Antibodies developed against recombinant VPX reacted with IBDV as
shown by indirect ELISA, reaching titers of about 106 (data
not shown). Similar results were obtained with the anti-VP3 serum. By
Western blot analysis, anti-VPX sera were shown to give a positive
signal with viral VPX and VP2 (Fig. 2A)
and anti-VP3 sera reacted strongly with VP3 and smaller forms of VP3
(Fig. 2B). As a positive control, two monospecific antisera
(anti-VPX/VP2 and anti-VP3) were made to react with the same viral
extracts (Fig. 2C).

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 2.
Recognition of IBDV VPX, VP2, and VP3 by rabbit
anti-recombinant VPX and VP3 sera. BGM70 cell extracts infected with
the SAL strain of IBDV were resolved by SDS-11% PAGE and
electroblotted onto a nitrocellulose sheet. The nitrocellulose was cut
into strips and incubated with rabbit anti-VPX serum (A), rabbit
anti-VP3 serum (B), and a mixture of rabbit monospecific sera against
VPX/VP2 and VP3 (C) as a positive control. Viral proteins are indicated
by arrows and arrowheads on the right of every strip. Molecular mass is
given in kilodaltons on the left.
|
|
The ability of recombinant VPX and VP3 to induce IBDV-neutralizing
antibodies was determined by a monolayer protection assay
using the
rabbit antisera and the two IBDV serotypes. The results
are
shown in Table
1. Rabbit serum
anti-VPX tubules neutralized
the serotype I virus at a titer of
12,800 and also were able to
cross-neutralize the serotype II virus,
albeit to a lesser extent
(titer, 100). However, the rabbit serum
elicited against VP3 showed
no detectable neutralization activity
(titer of <50).
Use of recombinant VPX and VP3 to detect IBDV-specific
antibodies.
An indirect ELISA was set up to determine the
effectivity of recombinant proteins VPX and VP3 as diagnostic reagents
for IBDV. Both proteins were tested using an indirect ELISA (Fig.
3). To test the specificity of the assay,
a collection of 150 positive chicken sera and 10 negative sera were
used at two different dilutions, 1:100 and 1:500. The cutoff value was
established with the 10 chicken sera, which were shown to be negative
for IBDV-specific antibodies, at 0.25 absorbance units. The cutoff
value represents an absorbance 2.5 times greater than that of the blank
sera. Sera with absorbance values greater than the cutoff were
considered positive. The VPX ELISA was more specific than the VP3
ELISA. At a 1:100 dilution, it was able to clearly discriminate the
negative from all the positive sera, including weakly positive sera and doubtful sera. In contrast, although the values of the negative sera
were lower with VP3, there was no clear discrimination between negative
and weakly positive sera, which is more relevant at a higher dilution
of the sera (1:500). Still, at a 1:100 dilution, the VP3 ELISA was
specific for positive and negative sera.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 3.
Use of recombinant VPX or VP3 in the IBDV-specific
ELISA. OD values were obtained with two dilutions (1/100 and 1/500) of
chicken sera. , negative samples; , positive samples. The
horizontal solid line corresponds to the cutoff value of 0.25.
|
|
Comparison of recombinant IBDV capsid proteins with commercial
ELISAs.
To evaluate the sensitivity and specificity of the
indirect ELISA, the results obtained with a collection of 300 field
chicken sera using our recombinant proteins VPX and VP3 were compared with those obtained with two commercial kits. Since recommended serum
dilutions for these two kits are different (1:500 for IDEXX and 1:100
for KPL), all samples were tested at these two dilutions for
comparison. Results, which are shown in Fig.
4 and 5 for
VPX and VP3 ELISA, respectively, were recorded as optical density (OD)
values obtained for each serum at each dilution. For VPX the best
correlation was obtained with the IDEXX kit at a dilution of 1:500
(Fig. 4B), with a correlation coefficient (R2)
of 0.837. At a 1:100 dilution the correlation coefficient was also
excellent (R2, 0.827) (Fig. 4A). With the KPL
ELISA, the correlation coefficient was lower at both dilutions
(R2 between 0.54 and 0.64) and values moved in a
broader range, but the results were still in good agreement (Fig. 4C
and D). For VP3 there was an overall lower correlation with both kits.
The best correlation (R2 = 0.643) was
obtained with the KPL kit at a 1:100 dilution (Fig. 5C). In this case,
the correlation of the results with those from the IDEXX kit was lower
(R 2 < 0.5) (Fig. 5A and B). On the basis
of these correlations, it is clear that the recombinant VPX-based ELISA
is a good alternative to currently available kits, yielding similar if
not superior results.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 4.
Correlation between the VPX-based ELISA and commercial
kits. OD measurements using the IDEXX kit were obtained by diluting the
chicken sera 1/500 and were compared with those obtained from serum
dilutions of 1/100 (A) and 1/500 (B) in the VPX ELISA. When the KPL kit
was used, chicken sera were diluted 1/100 and OD values were compared
with those obtained from serum dilutions of 1/100 (C) and 1/500 (D) in
the VPX ELISA. The linear regression formula and correlation
coefficient are shown at the top of each plot.
|
|

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 5.
Relationship between commercial kits and the VP3-based
ELISA. OD measurements using the IDEXX kit were obtained as for Fig. 4
and compared with those obtained from serum dilutions of 1/100 (A) and
1/500 (B) in the VP3 ELISA. When the KPL kit was used, chicken sera
were diluted 1/100 and OD values were compared with those obtained from
serum dilutions of 1/100 (C) and 1/500 (D) in the VP3 ELISA. The linear
regression formula and correlation coefficient are shown at the top of
each plot.
|
|
Correlation between seroneutralization and ELISA titers.
Seroneutralization is the reference technique for diagnosing IBDV.
Therefore, establishing a correlation with this technique is essential
to standardize any diagnostic technique. In order to make this
correlation, the same panel of sera was tested for neutralization.
Results are shown in Table 2. In general,
there was good agreement between the neutralization titers and the VPX ELISA; all the neutralization-positive sera were positive by ELISA. The
same situation was found with the commercial kits. In contrast, 10 neutralizing sera were not recognized in the VP3 ELISA. However, there
was a small percentage of sera in all the assays that were positive for
ELISA but negative for neutralization. This happened mainly with
low-titer sera. This could be explained by a major difference in
sensitivity between the ELISA and seroneutralization.
 |
DISCUSSION |
In the poultry field, where an enormous number of samples has to
be analyzed in a simple and economical way, cheap and reproducible antigens are essential. At the moment, the only kits available for the
detection and monitoring of IBDV antibodies are based on ELISAs that
use whole virions as the antigen. The propagation of IBDV in
embryonated eggs or in embryo cells is very time-consuming and
labor-intensive. In this study we investigated the two major IBDV
antigens, VPX and VP3 of the viral capsid, expressed in insect cells as
a feasible alternative in terms of safety and economy to these kits.
There have been some previous studies on the diagnostic use of
recombinant IBDV antigens (11, 13). However, none of the
reported antigens was identical to those described in this report,
purified VPX and VP3.
Recombinant baculovirus VPX presents the advantage of being a
particulate antigen, forming tubule-like structures, where the capsomer
structure is very similar if not identical to the virions (J. L. Martínez-Torrecuadrada et al., unpublished data). VPX as the
precursor of VP2 contains all the neutralizing domains and is probably
the critical protein for IBDV protection. VPX is expressed at higher
levels and is more easily purified than the polyprotein
(13). On the other hand, recombinant VP3 is overexpressed at
very high levels in the insect cells and can be easily purified. VP3
forms the scaffolding of the virion and is not accessible to antibodies
(Martínez-Torrecuadrada et al., submitted for
publication). Thus, it is well conserved in all the IBDV isolates
and could be of interest for the detection of invariant antibodies.
In both proteins, immunogenicity and antigenicity were well preserved
after expression, as the recombinant proteins were able to
satisfactorily immunize rabbits, eliciting a strong and specific immune
response. The polyclonal antisera allowed us to confirm the ability of
VPX to induce neutralizing antibodies in contrast to VP3, which was
completely inefficient. These results confirm previous observations of
the ability of VPX and VP2 to neutralize IBDV (1, 2, 4, 9,
24) and also show that the conformational neutralizing epitopes
are present in recombinant VPX, as was expected due to the similar
structure of the capsomers. However, they disagree with some previous
data on the neutralizing ability of VP3 (6, 21, 26).
Regarding the antigenicity, the dose required for coating the ELISA
plates is similar to or lower than the antigen concentration using
whole virus, confirming recombinant VPX's good antigenicity and
suitability as a diagnostic tool.
The correlation with the seroneutralization assay was similar to that
found with the IDEXX kit, which can be considered good and supports
even more the use of VPX as an antigen. The reasons some sera are
positive by ELISA and negative by neutralization are not completely
understood yet. Moreover, it is necessary to stress that most of the
sera with discrepant results gave low ELISA titers, suggesting that
these animals were weakly immunized or had low titers of antibody
against IBDV. Since the ELISA in general is more sensitive than other
serological techniques, it is not surprising that a few positive sera
are not identifiable by seroneutralization. Other possible reasons,
like the presence of variant strains, do not provide a consistent
explanation, as variability occurs even within animals from the same
farm, vaccinated according to the same protocols, and exposed to the
same environment.
In summary, the results of the present study regarding specificity,
sensitivity, and correlation with other diagnostic systems demonstrated
that recombinant VPX can be expressed in and purified from insect cells
cheaply and reproducibly. This recombinant protein, as well as
recombinant VP3, closely resembles the native proteins in size and
antigenicity. The ELISA developed with recombinant VPX was as sensitive
and specific as the conventional commercial kits, which use whole
virion as the antigen. On the basis of these results, the baculovirus
expression system is an excellent alternative for producing IBDV VPX at
high levels, which can be applied economically to detect and monitor
IBDV-specific antibodies in chickens and other avian species.
 |
ACKNOWLEDGMENTS |
We thank Y. Saif, J. C. Abad, and O. Vainio for kind supply
of materials and samples.
This project was partially funded by grant 09/038/1997 of the Comunidad
de Madrid.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: INGENASA, Hnos
Garcia Noblejas 41, 4, 28037 Madrid, Spain. Phone: 34 91 3680501. Fax: 34 91 4087598. E-mail: icasal{at}ingenasa.es.
 |
REFERENCES |
| 1.
|
Azad, A. A.,
M. N. Jagadish,
M. A. Brown, and P. J. Hudson.
1987.
Deletion mapping and expression in Escherichia coli of the large genomic segment of a birnavirus.
Virology
161:145-152[CrossRef][Medline].
|
| 2.
|
Becht, H.,
H. Muller, and H. K. Muller.
1988.
Comparative studies on structural and antigenic properties of two serotypes of infectious bursal disease virus.
J. Gen. Virol.
69:631-640[Abstract/Free Full Text].
|
| 3.
|
Dobos, P.,
B. J. Hill,
R. Hallett,
D. T. C. Kells,
H. Becht, and D. Teninges.
1979.
Biophysical and biochemical characterization of five animal viruses with bisegmented double-stranded RNA genomes.
J. Virol.
32:593-605[Abstract/Free Full Text].
|
| 4.
|
Fahey, K. J.,
K. Erny, and J. Crooks.
1989.
A conformational immunogen on VP-2 of infectious bursal disease virus that induces virus-neutralizing antibodies that passively protect chickens.
J. Gen. Virol.
70:1473-1481[Abstract/Free Full Text].
|
| 5.
|
Fahey, K. J.,
I. J. O'Donnell, and A. A. Azad.
1985.
Characterization by Western blotting of the immunogens of infectious bursal disease virus.
J. Gen. Virol.
66:1479-1488[Abstract/Free Full Text].
|
| 6.
|
Fahey, K. J.,
I. J. O'Donnell, and T. J. Bagust.
1985.
Antibody to the 32K structural protein of infectious bursal disease virus neutralizes viral infectivity in vitro and confers protection on young chickens.
J. Gen. Virol.
66:2693-2702[Abstract/Free Full Text].
|
| 7.
|
Fernández-Arias, A.,
S. Martínez, and J. F. Rodríguez.
1997.
The major antigenic protein of infectious bursal disease virus, VP2, is an apoptotic inducer.
J. Virol.
71:8014-8018[Abstract].
|
| 8.
|
Fernandez-Arias, A.,
C. Risco,
S. Martinez,
J. P. Albar, and J. F. Rodriguez.
1998.
Expression of ORF A1 of infectious bursal disease virus results in the formation of virus-like particles.
J. Gen. Virol.
79:1047-1054[Abstract].
|
| 9.
|
Heine, H. G.,
M. Haritou,
P. Failla,
K. Fahey, and A. Azad.
1991.
Sequence analysis and expression of the host-protective immunogen VP2 of a variant strain of infectious bursal disease virus which can circumvent vaccination with standard type I strains.
J. Gen. Virol.
72:1835-1843[Abstract/Free Full Text].
|
| 10.
|
Jackwood, D. H., and Y. M. Saif.
1987.
Antigenic diversity of infectious bursal disease viruses.
Avian Dis.
31:766-770[CrossRef][Medline].
|
| 11.
|
Jackwood, D. J.,
K. S. Henderson, and R. J. Jackwood.
1996.
Enzyme-linked immunosorbent assay-based detection of antibodies to antigenic subtypes of infectious bursal disease viruses of chickens.
Clin. Diagn. Lab. Immunol.
3:456-463[Abstract].
|
| 12.
|
Jackwood, D. J.,
Y. M. Saif, and J. H. Hughes.
1982.
Characteristics and serologic studies of two serotypes of infectious bursal disease virus in turkeys.
Avian Dis.
26:871-882[CrossRef][Medline].
|
| 13.
|
Jackwood, D. J.,
S. E. Sommer, and E. Odor.
1999.
Correlation of enzyme-linked immunosorbent assay titers with protection against infectious bursal disease virus.
Avian Dis.
43:189-197[CrossRef][Medline].
|
| 14.
|
Kibenge, F. S.,
A. S. Dhillon, and R. G. Russell.
1988.
Biochemistry and immunology of infectious bursal disease virus.
J. Gen. Virol.
69:1757-1775[Abstract/Free Full Text].
|
| 15.
|
Kitts, P. A., and R. D. Possee.
1993.
A method for producing recombinant baculovirus expression vectors at high frequency.
BioTechniques
14:810-817[Medline].
|
| 16.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[CrossRef][Medline].
|
| 16a.
|
Marquardt, W. W.,
R. B. Johnson,
W. F. Odenwald, and B. A. Schlotthober.
1980.
An indirect enzyme-linked immunosorbent assay (ELISA) for measuring antibodies in chickens infected with infectious bursal disease virus.
Avian Dis.
24:375-385[CrossRef][Medline].
|
| 17.
|
Martinez-Torrecuadrada, J. L.,
H. Iwata,
A. Venteo,
I. Casal, and P. Roy.
1994.
Expression and characterization of the two outer capsid proteins of African horsesickness virus: the role of VP2 in virus neutralization.
Virology
202:348-359[CrossRef][Medline].
|
| 18.
|
Matsuura, Y.,
R. D. Possee,
H. A. Overton, and D. H. L. Bishop.
1987.
Baculovirus expression vectors: the requirements for high level expression of proteins, including glycoproteins.
J. Gen. Virol.
68:1233-1250[Abstract/Free Full Text].
|
| 19.
|
Mayo, M. A., and C. R. Pringle.
1998.
Virus taxonomy 1997.
J. Gen. Virol.
79:649-657[Medline].
|
| 20.
|
Pitcovski, J.,
B. Z. Levi,
T. Maray,
D. Di-Castro,
A. Safadi,
S. Krispel,
A. Azriel,
B. Gutter, and A. Michael.
1999.
Failure of viral protein 3 of infectious bursal disease virus produced in prokaryotic and eukaryotic expression systems to protect chickens against the disease.
Avian Dis.
43:8-15[CrossRef][Medline].
|
| 21.
|
Possee, R. D., and S. C. Howard.
1987.
Analysis of the polyhedrin gene promoter of the Autographa californica nuclear polyhedrosis virus.
Nucleic Acids Res.
15:10233-10248[Abstract/Free Full Text].
|
| 22.
|
Reddy, S. K., and A. Silim.
1991.
Comparison of neutralizing antigens of recent isolates of infectious bursal disease virus.
Arch. Virol.
117:287-296[CrossRef][Medline].
|
| 23.
|
Reddy, S. K.,
A. Silim, and M. J. Ratcliffe.
1992.
Biological roles of the major capsid proteins and relationships between the two existing serotypes of infectious bursal disease virus.
Arch. Virol.
127:209-222[CrossRef][Medline].
|
| 24.
|
Sanchez, A. B., and J. F. Rodríguez.
1999.
Proteolytic processing in infectious bursal disease virus: identification of the polyprotein cleavage sites by site-directed mutagenesis.
Virology
262:190-199[CrossRef][Medline].
|
| 25.
|
Schoonjans, F.,
A. Zalata,
C. E. Depuydt, and F. H. Comhaire.
1995.
MedCalc: a new computer program for medical statistics.
Comput. Methods Programs Biomed.
48:257-262[CrossRef][Medline].
|
| 25a.
|
Thayer, S. G.,
P. Villegas, and O. J. Fletcher.
1987.
Comparison of two commercial enzyme-linked immunosorbent assays and conventional methods for avian serology.
Avian Dis.
31:120-124[CrossRef][Medline].
|
| 26.
|
Whetzel, P. L., and D. J. Jackwood.
1995.
Comparison of neutralizing epitopes among infectious bursal disease viruses using radioimmunoprecipitation.
Avian Dis.
39:499-506[CrossRef][Medline].
|
Clinical and Diagnostic Laboratory Immunology, July 2000, p. 645-651, Vol. 7, No. 4
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Caston, J. R., Martinez-Torrecuadrada, J. L., Maraver, A., Lombardo, E., Rodriguez, J. F., Casal, J. I., Carrascosa, J. L.
(2001). C Terminus of Infectious Bursal Disease Virus Major Capsid Protein VP2 Is Involved in Definition of the T Number for Capsid Assembly. J. Virol.
75: 10815-10828
[Abstract]
[Full Text]